Figure 5. Effect of B28Bn(6–14) treatment on prostate tumor growth in vivo. A.

. Effect of intratumoral injection. BALB/c nude mice bearing DU145 tumors were administered the peptide (5 mg/kg) or PBS daily on days 9-14 (arrows-indicated) post inoculation. ***, P<0.001 versus PBS from day 23 to the end, or B28 from day 25 to the end. B. B28Bn(6–14)-induced tumor tissue disruption. Mice bearing DU145 tumor grafts (200–300 mm³) were intratumorally administered a single, 50 µl dose of 50 µg B28Bn(6–14) or PBS. At 24 h post injection, the animals were sacrificed and the tumor tissues were routinely stained with H&E. C. Effect of intraperitoneal injection. Mice bearing tumors received the peptide (15 mg/kg) or PBS on days 7-13 (arrows-indicated) post inoculation. *, P<0.05 versus PBS or B28 from day 13 to the end. D. In vivo cytotoxicity of the liver and kidney was determined by histological examination. At the end of i.p. therapy with B28Bn(6–14) or PBS, liver and kidney from the sacrificed animals were routinely stained with H&E. The histopathologic architecture was analyzed by light microscopy. The original magnification was indicated. The tumor volume was calculated as length×width²×0.5. Differences in tumor growth were analyzed by one-way ANOVA test.